Bingham Private Wealth LLC Buys 4,827 Shares of Johnson & Johnson $JNJ

Key Points

• Bingham Private Wealth LLC increased its holdings in Johnson & Johnson by 123.7%, purchasing an additional 4,827 shares, bringing its total ownership to 8,728 shares.
• Johnson & Johnson's recent earnings report showed an EPS of $2.77, exceeding analysts' expectations, with revenue up 5.8% year-over-year at $23.74 billion.
• The company declared a quarterly dividend of $1.30 per share, resulting in an annualized yield of 2.7% for shareholders.

Bingham Private Wealth LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 123.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,728 shares of the company's stock after purchasing an additional 4,827 shares during the quarter. Johnson & Johnson comprises 1.2% of Bingham Private Wealth LLC's portfolio, making the stock its 18th largest holding. Bingham Private Wealth LLC's holdings in Johnson & Johnson were worth $1,333,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Apexium Financial LP boosted its position in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB lifted its holdings in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after buying an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC lifted its holdings in shares of Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after buying an additional 4,816 shares during the last quarter. Finally, Absher Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company's stock worth $35,752,000 after buying an additional 2,469 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $189.75 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The business has a fifty day simple moving average of $177.49 and a 200 day simple moving average of $163.37. Johnson & Johnson has a one year low of $140.68 and a one year high of $190.22. The firm has a market capitalization of $456.98 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 2.41 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the company posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on JNJ shares. The Goldman Sachs Group upped their price target on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. UBS Group set a $198.00 price target on Johnson & Johnson in a report on Friday, October 3rd. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Bank of America upped their target price on Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $189.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.